Physician profile
William White
NPI 1194704981
$3,050.11
in general payments reported to CMS, 2019-2025
33 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $378 · 2021: $476 · 2022: $595 · 2023: $349 · 2024: $453 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $468.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $422.80 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $268.46 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.17 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $190.06 | 2019-2022 | |
| Amgen INC. | $170.36 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.29 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $97.12 | 2019-2020 | |
| Exact Sciences Corporation | $91.50 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.70 | 2020-2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $77.55 | 2022-2025 | Airsupra |
| Esperion Therapeutics, INC. | $73.44 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $72.14 | 2019-2020 | |
| Abbott Laboratories | $71.30 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $68.90 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $63.74 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $49.87 | 2019-2021 | |
| Abbvie INC. | $46.31 | 2020-2024 | |
| Xeris Pharmaceuticals, INC. | $37.11 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $35.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $33.14 | 2019 | |
| Corium, LLC | $31.05 | 2022-2023 | Adlarity |
| Lundbeck LLC | $30.28 | 2023 | Rexulti |
| Shield Therapeutics INC | $30.22 | 2023-2024 | Accrufer |
| Biogen, INC. | $29.97 | 2020-2021 | |
| Eisai INC. | $25.73 | 2025 | |
| Stryker Corporation | $21.51 | 2025 | Molli |
| Paratek Pharmaceuticals, INC. | $20.13 | 2022 | |
| Irhythm Technologies, INC. | $17.84 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.50 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $14.60 | 2024 | Arexvy, Shingrix |
| Sanofi Pasteur INC. | $13.47 | 2019 | |
| Seqirus USA INC | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.